Table 2. Effects of treatment on bodyweight, blood pressure, glucose metabolism and lipid metabolism, and renal function.
| Sitagliptin | Other glucose‐lowering agents | |||||
|---|---|---|---|---|---|---|
| Baseline | 6 months | % Change | Baseline | 6 months | % Change | |
| Bodyweight (kg) | 68.0 ± 13.2 | 68.7 ± 13.6 | 1.0 ± 3.2 | 63.5 ± 13.4 | 62.5 ± 13.1 | −1.3 ± 6.0 |
| SBP (mmHg) | 126.6 ± 11.9 | 123.4 ± 16.6 | −2.3 ± 11.2 | 120.3 ± 8.8 | 118.5 ± 8.3 | −1.0 ± 9.5 |
| DBP (mmHg) | 72.2 ± 9.0 | 70.7 ± 9.1 | −1.3 ± 12.4 | 68.7 ± 7.6 | 68.9 ± 8.0 | 1.1 ± 13.5 |
| HbA1c (%) | 7.0 ± 0.7 | 6.4 ± 0.7* | −7.4 ± 6.2 | 6.9 ± 0.7 | 6.6 ± 0.7* | −4.5 ± 9.7 |
| FPG (mg/dL) | 138.1 ± 21.4 | 124.4 ± 17.6* | −9.2 ± 10.7 | 131.5 ± 26.0 | 122.9 ± 23.8* | −5.5 ± 14.1 |
| FPI (μU/ml) | 5.8 ± 3.6 | 5.9 ± 4.1 | 9.7 ± 54.2 | 6.9 ± 5.7 | 5.9 ± 4.1 | −0.4 ± 42.0 |
| HOMA‐IR | 2.0 ± 1.4 | 1.8 ± 1.4 | 1.5 ± 59.9 | 2.4 ± 2.3 | 1.9 ± 1.7 | −3.9 ± 44.2 |
| HOMA‐β (%) | 29.3 ± 19.4 | 36.1 ± 24.9* | 34.1 ± 56.5† | 37.0 ± 26.5 | 37.8 ± 27.9 | 14.2 ± 53.6 |
| LDL‐C (mg/dL) | 109.8 ± 29.4 | 102.6 ± 30.2* | −5.7 ± 16.1 | 103.7 ± 25.8 | 102.1 ± 27.0 | −0.2 ± 18.9 |
| HDL‐C (mg/dL) | 68.2 ± 16.2 | 66.4 ± 18.0 | −2.6 ± 14.6 | 62.8 ± 15.2 | 63.4 ± 17.4 | 2.1 ± 19.4 |
| TG (mg/dL) | 98.9 ± 41.7 | 84.4 ± 34.8* | −8.9 ± 36.5 | 112.1 ± 66.9 | 95.8 ± 51.0 | −4.1 ± 39.6 |
| eGFR (mL/min/1.73 m2) | 77.1 ± 18.9 | 73.7 ± 16.0* | −3.7 ± 8.2 | 75.5 ± 28.1 | 70.8 ± 21.3* | −4.8 ± 1.8 |
| Urine albumin (mg/gCre) | 68.9 ± 133.4 | 42.2 ± 126.4* | −36.3 ± 43.3† | 61.4 ± 154.3 | 81.2 ± 194.5 | 112.5 ± 255.0 |
| Log (urine albumin) | 1.3 ± 0.7 | 1.0 ± 0.6* | −23.3 ± 37.9 † | 1.2 ± 0.6 | 1.3 ± 0.6 | 0.8 ± 192.0 |
Values are mean ± standard deviation. *P < 0.05 vs baseline by Wilcoxon matched‐pairs signed‐rank test, †P < 0.05 vs other glucose‐lowering agents group by unpaired Mann–Whitney U‐test. DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; FPI, fasting plasma insulin; HbA1c, hemoglobin A1c; HOMA‐β, homeostasis model assessment β cell function; HOMA‐IR, homeostasis assessment model of insulin resistance; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride.